Category: Prostate Cancer

PSA is just a protein. It leaks into the bloodstream from healthy and unhealthy prostate cells alike, which means a high reading can signal cancer or nothing at all. Miami researchers found that men eating the most healthful plant-based diets had the lowest odds of an elevated PSA, and a 2024 study extends that benefit even after treatment. keep reading

Most men treated for early prostate cancer are alive five years later, whatever option they choose. So why do about 1 in 7 look back with regret? The answer has less to do with survival and more to do with side effects nobody prepared them for, and with how the decision got made in the first place. New long-term data adds urgency to that question. keep reading

Not every prostate cancer patient wants to choose between surgery and surveillance. Transperineal Focal Laser Ablation offers a third path, and it requires far less specialized equipment than MRI-guided ablation does. That makes the procedure shorter, simpler, less costly, and considerably easier for patients to access. keep reading

For localized prostate cancer, the options can feel like two extremes: treat the whole gland and risk lasting side effects, or treat none of it and live with the worry of watching and waiting. Focal therapy sits in between. By destroying just the tumor and a small margin around it, it aims for cancer control close to radical treatment while preserving the quality of life that comes with treating none of the gland. keep reading

Most men can name the usual prostate cancer risks: age, race, family history. A few others rarely make the list. Meat charred over high heat, how tall a boy grew during his teenage years, and even the kind of job a man works can each nudge his risk upward. None of them cause cancer outright, yet all three can tip the odds in ways worth understanding, and often in ways a man can act on. keep reading

Twenty-five years ago, most men diagnosed with localized prostate cancer were pointed toward one thing: surgery. Today the picture looks entirely different, with focal treatments and Active Surveillance firmly in the mainstream. The shift was not driven by fashion. It came from advanced imaging, more accurate biopsy, and long-term trial data that changed the calculus. keep reading

Most men over 45 grew up hearing that masturbation caused everything from blindness to acne. Harvard researchers found something closer to the opposite: men who ejaculated 21 times a month had a lower risk of prostate cancer than men who managed 4 to 7. A follow-up look at gene activity in prostate tissue hints at why that might be true. keep reading

Did you know over 95% of prostate cancers share the same name—adenocarcinoma? This common cell type is usually slow-growing, but not always. Understanding how it develops, why PSA levels matter, and what early detection can reveal is key to knowing your best treatment options. keep reading

Should every man on active surveillance be monitored the same way? New evidence suggests genetics may hold the answer. Polygenic risk scores could one day refine prostate cancer protocols, helping patients get care that matches their unique risk. keep reading

There's a saying that less is more. For men with intermediate-risk prostate cancer weighing hormone therapy on top of radiation, that phrase turns out to be more than a proverb. Five-year results from a landmark 1,492-patient trial found better cancer control in the combined group, no survival difference, and a real cost in side effects. keep reading